Fate Therapeutics (FATE) Misses Q3 EPS by 2c, Beats on Revenues

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.26), $0.02 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $1 million versus the consensus estimate of $930 thousand.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
• McCormick & Co. (MKC) Tops Q2 EPS by 10c ; Offers Guidance
• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story